<SEC-DOCUMENT>0000914475-21-000062.txt : 20211122
<SEC-HEADER>0000914475-21-000062.hdr.sgml : 20211122
<ACCEPTANCE-DATETIME>20211122080134
ACCESSION NUMBER:		0000914475-21-000062
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20211122
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211122
DATE AS OF CHANGE:		20211122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		211430196

	BUSINESS ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nbix-20211122.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:d8cf59c6-f4c9-4ffe-8861-14139fb379a0,g:f1c8ab55-edb2-4a33-a68e-6e57b5da5102,d:60ec3a59f2ea444593e9cc650557abfa--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nbix-20211122</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV80L2ZyYWc6NDFkYTg0N2Q4ZTJmNGI4MWFlZTM5YWY3YzFmMTc1ZmEvdGFibGU6ZTE0ZjI0NTRhYTVmNDhkNTgyMWM4NGQzMDZlMTI0MDUvdGFibGVyYW5nZTplMTRmMjQ1NGFhNWY0OGQ1ODIxYzg0ZDMwNmUxMjQwNV8wLTEtMS0xLTMyNjY0_64b36a45-78f9-4744-9762-e2259ed7a34b">false</ix:nonNumeric><ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV80L2ZyYWc6NDFkYTg0N2Q4ZTJmNGI4MWFlZTM5YWY3YzFmMTc1ZmEvdGFibGU6ZTE0ZjI0NTRhYTVmNDhkNTgyMWM4NGQzMDZlMTI0MDUvdGFibGVyYW5nZTplMTRmMjQ1NGFhNWY0OGQ1ODIxYzg0ZDMwNmUxMjQwNV8xLTEtMS0xLTMyNjY0_c46bd07d-19d2-4153-8de9-f6e5c97867f4">0000914475</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nbix-20211122.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-22</xbrli:startDate><xbrli:endDate>2021-11-22</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i60ec3a59f2ea444593e9cc650557abfa_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTcy_93b8f0f3-dd9e-492b-818c-ebed4763d698">8-K</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTY2_9b9883a8-73d3-48f2-aefd-5d22633cc280">November 22, 2021</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:21.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTY3_bf384034-5960-4319-b42c-e688f4b98d5b">NEUROCRINE BIOSCIENCES, INC.</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6M2YxMGNjN2I3NjIyNDMwMzgxYTUyNmFmODdhZTI1YmMvdGFibGVyYW5nZTozZjEwY2M3Yjc2MjI0MzAzODFhNTI2YWY4N2FlMjViY18wLTAtMS0xLTMyNjY0_7d67d125-bea4-45a5-8195-cb22549d73af">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6M2YxMGNjN2I3NjIyNDMwMzgxYTUyNmFmODdhZTI1YmMvdGFibGVyYW5nZTozZjEwY2M3Yjc2MjI0MzAzODFhNTI2YWY4N2FlMjViY18wLTEtMS0xLTMyNjY0_c4c51944-5a69-4265-b479-31285899781a">0-22705</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6M2YxMGNjN2I3NjIyNDMwMzgxYTUyNmFmODdhZTI1YmMvdGFibGVyYW5nZTozZjEwY2M3Yjc2MjI0MzAzODFhNTI2YWY4N2FlMjViY18wLTItMS0xLTMyNjY0_37bd3616-42cf-4b0a-b7d5-f6b90d825c61">33-0525145</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(State or Other Jurisdiction</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(Commission</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:64.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(IRS Employer</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:64.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:63.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6M2YxMGNjN2I3NjIyNDMwMzgxYTUyNmFmODdhZTI1YmMvdGFibGVyYW5nZTozZjEwY2M3Yjc2MjI0MzAzODFhNTI2YWY4N2FlMjViY180LTAtMS0xLTMyNjY0_f9061f56-6ecf-4740-9ca7-183e40d2fa32">12780 El Camino Real,</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:62.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6M2YxMGNjN2I3NjIyNDMwMzgxYTUyNmFmODdhZTI1YmMvdGFibGVyYW5nZTozZjEwY2M3Yjc2MjI0MzAzODFhNTI2YWY4N2FlMjViY181LTAtMS0xLTMyNjY0_294f1a30-cd8a-4cb4-a4b3-9e1cbc4c60a4">San Diego,</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6M2YxMGNjN2I3NjIyNDMwMzgxYTUyNmFmODdhZTI1YmMvdGFibGVyYW5nZTozZjEwY2M3Yjc2MjI0MzAzODFhNTI2YWY4N2FlMjViY181LTEtMS0xLTMyNjY0_21ba050c-4b0b-482d-894f-1902619b2fbe">California</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6M2YxMGNjN2I3NjIyNDMwMzgxYTUyNmFmODdhZTI1YmMvdGFibGVyYW5nZTozZjEwY2M3Yjc2MjI0MzAzODFhNTI2YWY4N2FlMjViY181LTItMS0xLTMyNjY0_d5bdbf3c-0652-496f-9955-bb429cfef637">92130</ix:nonNumeric></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:62.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:64.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTY4_163927f1-8771-4c66-99cb-995880cc30cb">858</ix:nonNumeric>) <ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTcz_673a607b-a2a1-4b0e-9c45-4ebad098cf8a">617-7600</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Title of each class</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Name of each exchange on which registered</span></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6NDU4NTlkOWQzZTUwNGI3NTkxYThlMGVlMmQxODViN2UvdGFibGVyYW5nZTo0NTg1OWQ5ZDNlNTA0Yjc1OTFhOGUwZWUyZDE4NWI3ZV8yLTAtMS0xLTMyNjY0_c2177b19-8746-4867-a12c-cb319c6bb68a">Common Stock, $0.001 par value</ix:nonNumeric></span></div></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6NDU4NTlkOWQzZTUwNGI3NTkxYThlMGVlMmQxODViN2UvdGFibGVyYW5nZTo0NTg1OWQ5ZDNlNTA0Yjc1OTFhOGUwZWUyZDE4NWI3ZV8yLTItMS0xLTMyNjY0_6980ca15-a7e9-4272-8b6b-0eed23c112f7">NBIX</ix:nonNumeric></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6NDU4NTlkOWQzZTUwNGI3NTkxYThlMGVlMmQxODViN2UvdGFibGVyYW5nZTo0NTg1OWQ5ZDNlNTA0Yjc1OTFhOGUwZWUyZDE4NWI3ZV8yLTQtMS0xLTMyNjY0_d210c4d6-ccc8-41eb-91c7-6479ed5f9312">Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTY5_c8556063-e77e-4955-84b5-4eebc4f0612d">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTc0_9a72a650-c0ff-4dfa-8fdd-fe7440df357f">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTc1_1479113b-1a6a-44c7-88ca-eaec7ff380c1">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTcw_cd976e1d-2899-4a3f-bac6-e61a4067b738">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTcx_e100ebc5-c845-4c86-88ca-2b72ddaaec42">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i60ec3a59f2ea444593e9cc650557abfa_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Entry into a Material Definitive Agreement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2021 (the &#8220;Agreement Date&#8221;), Neurocrine Biosciences, Inc. (the &#8220;Company&#8221;) entered into a Collaboration and License Agreement (the &#8220;License Agreement&#8221;) with Heptares Therapeutics Limited (&#8220;Heptares&#8221;), an affiliate of the Sosei Group Corporation, for the development and commercialization of products containing certain sub-type selective muscarinic M1, M4 or dual M1/M4 receptor agonists (collectively, the &#8220;Licensed Products&#8221;).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the License Agreement, upon the expiration or termination of applicable waiting periods and the receipt of any required approvals or clearances under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (such date, the &#8220;Effective Date&#8221; and such clearance, &#8220;Antitrust Clearance&#8221;), Heptares has agreed to grant the Company an exclusive, sublicensable license to certain of its intellectual property rights in all fields of use in the Territory to develop, manufacture and commercialize the Licensed Products. &#8220;Territory&#8221; means worldwide, excluding Japan for Licensed Products comprised of M1 receptor agonists (the &#8220;M1 Licensed Products&#8221;), subject to the Company&#8217;s option for M1 Licensed Products in Japan described below. Heptares has also granted the Company a non-exclusive, sublicensable license to its platform intellectual property in all fields of use in the Territory to the extent necessary to develop, commercialize and exploit the Licensed Products under the exclusive license. Heptares has retained the rights to develop, manufacture and commercialize the M1 Licensed Products in Japan, subject to the Company&#8217;s option in Japan.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development in the Territory.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the License Agreement, Heptares is responsible for the completion of any ongoing or future non-clinical activities or other activities as approved by a joint steering committee (the &#8220;JSC&#8221;) for the Licensed Products. The Company has the option to engage Heptares to carry out Phase I clinical trials for certain Licensed Products. The Company is responsible for all development costs and all other development, regulatory, and commercialization activities for the Licensed Products in the Territory. The JSC will monitor and provide strategic oversight of the activities under the License Agreement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development in Japan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Heptares is responsible for the development of the M1 Licensed Products in Japan, subject to oversight by the JSC. The Company has the option to fund a portion of the development costs of M1 Licensed Products in Japan incurred after exercise of the option and to receive a portion of the revenues resulting from commercialization of M1 Licensed Products in Japan. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the terms of the License Agreement, the Company has agreed to pay Heptares an upfront payment of $100.0 million within 10 days of the Effective Date. In addition, Heptares is eligible to receive development and regulatory milestones of up to approximately $1.5 billion in the aggregate (for both clinical and non-clinical stage compounds) and commercial milestones of up to approximately $1.1 billion in the aggregate. The Company has also agreed to pay Heptares tiered royalties from the high single digit to mid-teen percentage rates on future net sales of Licensed Products in the Territory. On a country-by-country and Licensed Product-by-Licensed Product basis, royalty payments would commence on the first commercial sale of a Licensed Product and terminate on the later of (i) the expiration of the last patent covering such Licensed Product in such country, (ii) a number of years from the first commercial sale of such Licensed Product in such country and (iii) the expiration of regulatory exclusivity for such Licensed Product in such country (the &#8220;Royalty Term&#8221;).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Termination.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unless earlier terminated, the License Agreement will continue on a Licensed Product-by-Licensed Product and country-by-country basis until the date on which the Royalty Term for such Licensed Product has expired in such country. Prior to the second anniversary of the Effective Date or such other date set by the JSC (the &#8220;Research Term&#8221;), the Company may terminate the License Agreement for convenience in its entirety or with respect to one or more targets (M1, M4 or dual M1/M4) upon 180 days&#8217; written notice to Heptares. After the Research Term, the Company may terminate the License Agreement for convenience in its entirety or with respect to one or more targets upon 90 days&#8217; written notice to Heptares. After the Research Term, Heptares may terminate the License Agreement on a target-by-target basis in the event that the Company does not conduct any material development activities in the Territory with respect to Licensed Products within the applicable target class for a continuous period not less than 365 days and does not commence any such activities within 120 days of receiving written notice.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either party may terminate the License Agreement, subject to specified conditions, (i) in the event of material breach by the other party, subject to a cure period, (ii) if the other party challenges the validity or enforceability of certain intellectual property rights, subject to a cure period, or (iii) if the other party becomes insolvent or takes certain actions related to insolvency. Either party </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may also terminate the License Agreement if the parties are unable to obtain Antitrust Clearance within 120 days of the Agreement Date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the material terms of the License Agreement is qualified in its entirety by reference to the full text of the License Agreement, a copy of which will be filed as an exhibit to a subsequent filing with the Securities and Exchange Commission.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Special Note Regarding Forward-Looking Statements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Current Report on Form 8-K contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause the Company&#8217;s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;expects&#8221;, &#8220;plans&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;projects&#8221;, &#8220;predicts&#8221;, &#8220;potential&#8221; and similar expressions intended to identify forward-looking statements. These statements include, but are not limited to, statements related to the potential benefits of the collaboration with Heptares, the total potential deal value of the collaboration and the ability to obtain Antitrust Clearance. These statements reflect the Company&#8217;s current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.418%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nbix-20211122exhibit991.htm">Press Release dated November 22, 2021</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i60ec3a59f2ea444593e9cc650557abfa_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEUROCRINE BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November 22, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Darin M. Lippoldt</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Darin M. Lippoldt</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Legal Officer</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nbix-20211122exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4041b46e0bfd4daa841e3429ea5583c6_33"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878 in schizophrenia in 2022 and Phase 1 studies for a dual M1&#47;M4 and selective M1 agonist in 2023</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sosei Heptares receives US$100 million upfront, ongoing R&#38;D funding, and up to US$2.6 billion in potential development, regulatory and commercial milestone payments, plus tiered sales royalties</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SAN DIEGO, Calif., USA, TOKYO, Japan and CAMBRIDGE, UK. Nov. 22 2021</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Neurocrine Biosciences, Inc. (Nasdaq&#58; NBIX) and Sosei Group Corporation (&#8220;Sosei Heptares&#8221;&#59; TSE&#58; 4565) announce the signing of a strategic collaboration and licensing agreement to develop novel muscarinic receptor agonists, which Neurocrine Biosciences intends to study in the treatment for schizophrenia, dementia and other neuropsychiatric disorders.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Neurocrine Biosciences gains development and commercialization rights to a broad portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1&#47;M4 receptor agonists discovered by Sosei Heptares in development for the treatment of major neurological disorders. The most advanced program, HTL-0016878, is a selective M4 agonist. Neurocrine Biosciences plans to submit an Investigational New Drug (IND) application and initiate a placebo-controlled Phase 2 study with HTL-0016878 as a potential treatment for schizophrenia in 2022. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sosei Heptares retains the rights to develop M1 agonists in Japan in all indications, with Neurocrine Biosciences receiving co-development and profit share options. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Muscarinic receptors are central to brain function and validated as drug targets in psychosis and cognitive disorders. Sosei Heptares has discovered selective muscarinic M4, M1 and M1&#47;M4 dual agonists that offer the potential to deliver therapeutic effects while avoiding both the harmful side effects caused by non-selective agonists and efficacy issues experienced in some older patients caused by positive allosteric modulators that require cooperativity of diminishing levels of acetylcholine. Sosei Heptares achieved this through application of its world leading G protein-coupled receptor (GPCR) stabilized receptor platform (StaR&#174;) and subsequent translational medicine studies. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Our partnership collaboration with Sosei Heptares to advance their selective muscarinic agonist portfolio leverages the strengths of both our organizations with one goal in mind, to bring important medicines to patients who need better treatment options,&#8221; said Kevin Gorman, Ph.D., Chief Executive Officer at Neurocrine Biosciences. &#8220;We continue to add potential best-in-class compounds to our growing pipeline, which further positions Neurocrine Biosciences as a leading neuroscience-focused biopharmaceutical company.&#8221;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shinichi Tamura, President and CEO of Sosei Heptares, added&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;We are delighted to partner with Neurocrine Biosciences to advance our selective muscarinic receptor agonist portfolio. The deal highlights the significant potential value within this portfolio and brings to bear the substantial expertise of the Neurocrine team, which is highly experienced in developing and commercializing novel products for patients with neurological and psychiatric diseases globally. It also enables Sosei Heptares to retain rights in Japan, where we are confident that we can make important progress leveraging our own expertise to advance novel candidates that aim to address this major unmet need. Overall, the deal is a great example of our strategy to combine our drug design and early development capabilities with those of later stage development and commercialization partners, while also providing significant funding to expand and advance our own pipeline.&#8221;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Details</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Neurocrine Biosciences will be responsible for development costs associated with the programs globally, except for M1 agonists being developed in Japan. The agreement will be subject to the following terms&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Upfront License Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; Sosei Heptares will receive a total of $100 million USD in upfront cash.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Development and Regulatory Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; Sosei Heptares is eligible to receive up to approximately $1.5 billion USD related to the successful progression of licensed candidates through to regulatory approval.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Commercial Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; Sosei Heptares is eligible to receive up to $1.1 billion USD upon achieving certain global sales milestones of any products developed under the partnership</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Product Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; Sosei Heptares is eligible to receive tiered royalties ranging from high single digit to mid-teen percentage on future net sales of any products developed under the partnership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">R&#38;D Collaboration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; The R&#38;D collaboration will be conducted jointly by Neurocrine Biosciences and Sosei Heptares to advance preclinical candidates through Phase 1 clinical studies. The R&#38;D collaboration will be funded by Neurocrine Biosciences.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Sosei Heptares M1 Agonist Rights in Japan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; Sosei Heptares retains rights to develop M1 agonists in Japan for any indication, with Neurocrine Biosciences receiving co-development and profit share options.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This transaction is subject to customary clearances under the Hart-Scott-Rodino Antitrust Improvements Act. Assuming this transaction completes by December 31, 2021, the $100 million USD upfront payment will represent a material positive revenue impact to Sosei Heptares, and is expected to be recognized as revenue in the fourth quarter of the financial year ended December 31, 2021, subject to agreement with the Group&#8217;s auditors. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BofA Securities is acting as financial advisor to Sosei Heptares. Gowling WLG and Orrick Herrington &#38; Sutcliffe LLP are serving as legal counsel to Sosei Heptares.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call and Webcast Information</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 23, Sosei Heptares will host a conference call and webinar for Japanese investors on at 8&#58;00 a.m. Japan Standard Time. The live call may be accessed by pre-registration here.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A live audio webcast of the conference call will be available from the Investors section of Sosei Heptares website at www.soseiheptares.com. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A replay of the webcast will be available on Sosei Heptares&#8217; website after the conclusion of the event and will be archived for approximately one month.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Muscarinic Receptors </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Muscarinic receptors are G protein-coupled receptors (GPCRs) found in multiple tissues including the brain, cardiovascular system, and gastrointestinal tract. Selective activation of M4 and M1 receptors in the brain is a clinically validated approach to treating cognitive and neuropsychological symptoms of neurological diseases, including Schizophrenia, dementia associated with Alzheimer&#8217;s disease, Parkinson&#8217;s disease, and others. Until now, attempts to develop medicines that selectively target M4 and M1 receptors have been unsuccessful because of side effects caused by the activation of M2 and M3 receptors. Highly selective M4 or M1 agonists that do not activate M2 or M3 therefore are highly sought after and expected to have the potential to address major unmet medical needs with blockbuster potential.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Programs in the Collaboration Agreement</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HTL-0016878</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HTL-0016878 (&#8220;878&#8221;) is an oral, investigational M4 selective agonist that has completed multiple Phase 1 studies and is preparing for the initiation of Phase 2 studies in schizophrenia. As a selective M4 orthosteric agonist, &#8216;878 offers the potential for an improved safety profile without the need of combination therapy to minimize side effects and avoids the need of cooperativity with acetylcholine (ACh) when compared to non-selective muscarinic agonists and positive allosteric modulators in development. Studies completed to date have shown &#8216;878 to be generally well tolerated. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preclinical Programs</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration includes rights to multiple preclinical programs which include selective muscarinic compounds targeting M1, M4 receptors and a dual M1&#47;M4 receptor candidate. In combination with &#8216;878, the programs offer the ability to leverage M1 and M4 selectivity to address the unmet need for patients suffering from psychosis and cognitive-related diseases.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After signing a R&#38;D and commercialization partnership in 2016, Allergan returned all program rights to &#8216;878 and the preclinical programs to Sosei Heptares in Q1 2021.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Neurocrine Biosciences</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie).</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Sosei Heptares</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR&#174; technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology, and inflammatory diseases. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established partnerships with some of the world&#8217;s leading pharmaceutical companies and multiple emerging technology companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Neurocrine Biosciences, Pfizer, and Takeda. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&#38;D facilities in Cambridge, UK.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Sosei Heptares&#8221; is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker&#58; 4565). Sosei, Heptares, the logo and StaR&#174; are trademarks of Sosei Group companies. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information, please visit https&#58;&#47;&#47;soseiheptares.com&#47;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LinkedIn&#58; &#64;soseiheptaresco &#124; Twitter&#58; &#64;soseiheptaresco &#124; YouTube&#58; &#64;soseiheptaresco</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Enquiries&#58; </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For Neurocrine Biosciences</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tony Jewell, Media</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+1 858-617-7578, media&#64;neurocrine.com</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Todd Tushla Investors</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+1 858-617-7143, ir&#64;neurocrine.com</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For Sosei Heptares</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hironoshin Nomura, SVP Investor Relations and Corporate Strategy </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+81 (0)3 6679 2178, Hironoshin.Nomura&#64;SoseiHeptares.com</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+81 (0)3 5210 3399, IR&#64;SoseiHeptares.com</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Citigate Dewe Rogerson (for Japanese Media)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yas Fukuda </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+81 (0)3 4360 9234, Yas.Fukuda&#64;citigatedewerogerson.com</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDiSTRAVA Consulting (for International Media)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mark Swallow, David Dible, Eleanor Perkin</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+44 (0)20 7638 9571, SoseiHeptares&#64;medistrava.com</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neurocrine Biosciences Forward-looking statements</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to the benefits to be derived from transactions with Sosei Group Corporation&#59; our potential milestone and royalty payments to Sosei Heptares&#59; the development of our product candidates and the timing of completion of our clinical, regulatory, and other development activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">the possibility that the transaction with Sosei Heptares is not consummated on the expected timeline or at all or the possibility that regulatory approvals of the proposed transaction will impose conditions or are not obtained&#59; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and resulting global, national, and local economic and financial disruptions&#59; risks and uncertainties related to any COVID-19 quarantines, shelter-in-place and similar government orders that are currently in place or that may be put in place in the future, including the impact of such orders on our business operations and the business operations of the third parties on which we rely&#59; our future financial and operating performance&#59; risks or </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">uncertainties related to the development of the our product candidates&#59; risks that the FDA or other regulatory authorities may make adverse decisions regarding our product candidates&#59; risks that clinical development activities may not be completed on time or at all&#59; risks that clinical development activities may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials&#59; risks and uncertainties relating to competitive products and technological changes that may limit demand for a product candidate&#59; risks that the benefits of the agreements with Sosei Heptares may never be realized&#59; risks that our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse&#59; and other risks described in our periodic reports filed with the SEC, including without limitation our quarterly report on Form 10-Q for the quarter ended September 30, 2021. Neurocrine disclaims any obligation to update the statements contained in this press release after the date hereof.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sosei Group Corporation Forward-looking statements</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Sosei Group Corporation&#8217;s actual results to differ materially from those expressed or implied by the forward-looking statements, including&#58; adverse results in clinical development programs&#59; failure to obtain patent protection for inventions&#59; commercial limitations imposed by patents owned or controlled by third parties&#59; dependence upon strategic alliance partners to develop and commercialize products and services&#59; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts&#59; the requirement for substantial funding to conduct research and development and to expand commercialization activities&#59; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>nbix-20211122.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d8cf59c6-f4c9-4ffe-8861-14139fb379a0,g:f1c8ab55-edb2-4a33-a68e-6e57b5da5102-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbix="http://www.neurocrine.com/20211122" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurocrine.com/20211122">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20211122_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20211122_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.neurocrine.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>nbix-20211122_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d8cf59c6-f4c9-4ffe-8861-14139fb379a0,g:f1c8ab55-edb2-4a33-a68e-6e57b5da5102-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_db433814-762b-421c-bd20-3d8c4937e7c7_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ee662f97-2931-437b-a3f3-74886a882748_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2bc5ec6c-f0c7-42c4-92e2-1fecdebef564_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7a2b1346-9e69-4ae0-8c90-1c107264581b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0353ce07-03fc-4687-8f6d-138b4659fa23_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_dccc9fcb-d48e-4a0d-b48a-31f7bd3abaaf_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_620f41c6-2dcb-4f15-bb13-2f5019be9eee_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_b1426b71-b3cf-44c9-ae66-1e11682efc33_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_405b2ed9-cf80-4660-95d0-99f3e5b01175_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fa2e0137-2bd1-488c-a37a-b4823887e060_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_fb7ce6e5-8fe3-4476-a868-5e9b71bdf34f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_beaca0ee-16ae-4ffa-bbbb-61bf91941d4d_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b8c10b1f-be57-4f46-a8bd-6c552b97c4c9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4f79a40a-9428-4d03-a626-335fd2ddd051_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_30946409-b8ab-4921-8e5c-2ac3b0fbff5f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7e1ffce4-38cd-4376-9010-a14f759ae137_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_0f444910-d2eb-49b7-8087-b64cf1dfa8aa_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a47091dc-61bc-4ba6-b20e-78f55f619505_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c52f1417-bc36-454c-8296-b9939a39fc03_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ba1d801f-c235-483e-b415-ed59360d1661_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_44e96e4f-d20e-4eed-b03f-d6eb04a443b3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3c903b70-0bf4-480c-93d7-ee5ae3a58807_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>nbix-20211122_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d8cf59c6-f4c9-4ffe-8861-14139fb379a0,g:f1c8ab55-edb2-4a33-a68e-6e57b5da5102-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/Cover" xlink:type="simple" xlink:href="nbix-20211122.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_cc83a7a1-9a64-4610-af7e-f8a1f53c1647" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_DocumentType_cc83a7a1-9a64-4610-af7e-f8a1f53c1647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_119ee518-e97a-4a89-a950-59b271da457d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_DocumentPeriodEndDate_119ee518-e97a-4a89-a950-59b271da457d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_18728298-0be6-4926-b9d5-dc659f5f076a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_EntityRegistrantName_18728298-0be6-4926-b9d5-dc659f5f076a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_79df3c00-9f42-48c5-a075-e4d5fcbbdc4f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_79df3c00-9f42-48c5-a075-e4d5fcbbdc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7e5f4b10-b3d1-4777-ba2e-01bc27010cac" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_EntityFileNumber_7e5f4b10-b3d1-4777-ba2e-01bc27010cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_68a9a86f-ae0b-4c0e-90ad-48dfbf596a0d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_EntityTaxIdentificationNumber_68a9a86f-ae0b-4c0e-90ad-48dfbf596a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2c6ae8d4-20fb-4148-9397-40b12c2ce3e0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_EntityAddressAddressLine1_2c6ae8d4-20fb-4148-9397-40b12c2ce3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_89a654b6-99c9-42f1-b107-2008ccfcd6bc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_EntityAddressCityOrTown_89a654b6-99c9-42f1-b107-2008ccfcd6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c9ef18bd-f16b-443b-9dab-44a3253d6f87" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_EntityAddressStateOrProvince_c9ef18bd-f16b-443b-9dab-44a3253d6f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b93f3af9-1a67-44a2-be39-4feb1a45b274" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_EntityAddressPostalZipCode_b93f3af9-1a67-44a2-be39-4feb1a45b274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5e67dda9-0c8a-49a2-8112-135a4054c8c8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_CityAreaCode_5e67dda9-0c8a-49a2-8112-135a4054c8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8f6d2f49-944e-46c3-a0ba-e288103d4c68" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_LocalPhoneNumber_8f6d2f49-944e-46c3-a0ba-e288103d4c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_22e12f72-704b-417d-8f92-1560b57a0c2e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_Security12bTitle_22e12f72-704b-417d-8f92-1560b57a0c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_63dd1a8c-2cc5-4592-afad-bf279712c4bd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_TradingSymbol_63dd1a8c-2cc5-4592-afad-bf279712c4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_daa96c4e-7d8b-4bd9-9dde-9532f7c74b68" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_SecurityExchangeName_daa96c4e-7d8b-4bd9-9dde-9532f7c74b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_d66b80df-2dc2-468c-928b-faf12096fee4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_WrittenCommunications_d66b80df-2dc2-468c-928b-faf12096fee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_36ddf9bb-1c69-4d16-8b4c-54eba2f86c3c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_SolicitingMaterial_36ddf9bb-1c69-4d16-8b4c-54eba2f86c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_c0070cf2-3e84-4482-9ac3-fea521476077" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_PreCommencementTenderOffer_c0070cf2-3e84-4482-9ac3-fea521476077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_9dd9674f-7293-4e1a-96f2-772b0d10854f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_9dd9674f-7293-4e1a-96f2-772b0d10854f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_414d7181-7706-4def-a872-32eeca332024" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_EntityEmergingGrowthCompany_414d7181-7706-4def-a872-32eeca332024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5d47c819-da7f-47e9-84cf-e96731b07e15" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_AmendmentFlag_5d47c819-da7f-47e9-84cf-e96731b07e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a6ae131d-93e9-40c4-ba66-5282ec58000e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e434301-615f-478e-b17a-94ba3391e93e" xlink:to="loc_dei_EntityCentralIndexKey_a6ae131d-93e9-40c4-ba66-5282ec58000e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>nbix-20211122_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nbix-20211122.xsd" xlink:type="simple"/>
    <context id="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2021-11-22</startDate>
            <endDate>2021-11-22</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV80L2ZyYWc6NDFkYTg0N2Q4ZTJmNGI4MWFlZTM5YWY3YzFmMTc1ZmEvdGFibGU6ZTE0ZjI0NTRhYTVmNDhkNTgyMWM4NGQzMDZlMTI0MDUvdGFibGVyYW5nZTplMTRmMjQ1NGFhNWY0OGQ1ODIxYzg0ZDMwNmUxMjQwNV8wLTEtMS0xLTMyNjY0_64b36a45-78f9-4744-9762-e2259ed7a34b">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV80L2ZyYWc6NDFkYTg0N2Q4ZTJmNGI4MWFlZTM5YWY3YzFmMTc1ZmEvdGFibGU6ZTE0ZjI0NTRhYTVmNDhkNTgyMWM4NGQzMDZlMTI0MDUvdGFibGVyYW5nZTplMTRmMjQ1NGFhNWY0OGQ1ODIxYzg0ZDMwNmUxMjQwNV8xLTEtMS0xLTMyNjY0_c46bd07d-19d2-4153-8de9-f6e5c97867f4">0000914475</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTcy_93b8f0f3-dd9e-492b-818c-ebed4763d698">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTY2_9b9883a8-73d3-48f2-aefd-5d22633cc280">2021-11-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTY3_bf384034-5960-4319-b42c-e688f4b98d5b">NEUROCRINE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6M2YxMGNjN2I3NjIyNDMwMzgxYTUyNmFmODdhZTI1YmMvdGFibGVyYW5nZTozZjEwY2M3Yjc2MjI0MzAzODFhNTI2YWY4N2FlMjViY18wLTAtMS0xLTMyNjY0_7d67d125-bea4-45a5-8195-cb22549d73af">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6M2YxMGNjN2I3NjIyNDMwMzgxYTUyNmFmODdhZTI1YmMvdGFibGVyYW5nZTozZjEwY2M3Yjc2MjI0MzAzODFhNTI2YWY4N2FlMjViY18wLTEtMS0xLTMyNjY0_c4c51944-5a69-4265-b479-31285899781a">0-22705</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6M2YxMGNjN2I3NjIyNDMwMzgxYTUyNmFmODdhZTI1YmMvdGFibGVyYW5nZTozZjEwY2M3Yjc2MjI0MzAzODFhNTI2YWY4N2FlMjViY18wLTItMS0xLTMyNjY0_37bd3616-42cf-4b0a-b7d5-f6b90d825c61">33-0525145</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6M2YxMGNjN2I3NjIyNDMwMzgxYTUyNmFmODdhZTI1YmMvdGFibGVyYW5nZTozZjEwY2M3Yjc2MjI0MzAzODFhNTI2YWY4N2FlMjViY180LTAtMS0xLTMyNjY0_f9061f56-6ecf-4740-9ca7-183e40d2fa32">12780 El Camino Real,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6M2YxMGNjN2I3NjIyNDMwMzgxYTUyNmFmODdhZTI1YmMvdGFibGVyYW5nZTozZjEwY2M3Yjc2MjI0MzAzODFhNTI2YWY4N2FlMjViY181LTAtMS0xLTMyNjY0_294f1a30-cd8a-4cb4-a4b3-9e1cbc4c60a4">San Diego,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6M2YxMGNjN2I3NjIyNDMwMzgxYTUyNmFmODdhZTI1YmMvdGFibGVyYW5nZTozZjEwY2M3Yjc2MjI0MzAzODFhNTI2YWY4N2FlMjViY181LTEtMS0xLTMyNjY0_21ba050c-4b0b-482d-894f-1902619b2fbe">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6M2YxMGNjN2I3NjIyNDMwMzgxYTUyNmFmODdhZTI1YmMvdGFibGVyYW5nZTozZjEwY2M3Yjc2MjI0MzAzODFhNTI2YWY4N2FlMjViY181LTItMS0xLTMyNjY0_d5bdbf3c-0652-496f-9955-bb429cfef637">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTY4_163927f1-8771-4c66-99cb-995880cc30cb">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTcz_673a607b-a2a1-4b0e-9c45-4ebad098cf8a">617-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6NDU4NTlkOWQzZTUwNGI3NTkxYThlMGVlMmQxODViN2UvdGFibGVyYW5nZTo0NTg1OWQ5ZDNlNTA0Yjc1OTFhOGUwZWUyZDE4NWI3ZV8yLTAtMS0xLTMyNjY0_c2177b19-8746-4867-a12c-cb319c6bb68a">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6NDU4NTlkOWQzZTUwNGI3NTkxYThlMGVlMmQxODViN2UvdGFibGVyYW5nZTo0NTg1OWQ5ZDNlNTA0Yjc1OTFhOGUwZWUyZDE4NWI3ZV8yLTItMS0xLTMyNjY0_6980ca15-a7e9-4272-8b6b-0eed23c112f7">NBIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGFibGU6NDU4NTlkOWQzZTUwNGI3NTkxYThlMGVlMmQxODViN2UvdGFibGVyYW5nZTo0NTg1OWQ5ZDNlNTA0Yjc1OTFhOGUwZWUyZDE4NWI3ZV8yLTQtMS0xLTMyNjY0_d210c4d6-ccc8-41eb-91c7-6479ed5f9312">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTY5_c8556063-e77e-4955-84b5-4eebc4f0612d">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTc0_9a72a650-c0ff-4dfa-8fdd-fe7440df357f">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTc1_1479113b-1a6a-44c7-88ca-eaec7ff380c1">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTcw_cd976e1d-2899-4a3f-bac6-e61a4067b738">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwZWMzYTU5ZjJlYTQ0NDU5M2U5Y2M2NTA1NTdhYmZhL3NlYzo2MGVjM2E1OWYyZWE0NDQ1OTNlOWNjNjUwNTU3YWJmYV8xL2ZyYWc6MmQ0N2ZmMDBjYWU5NDgyZjhmMDg2MGRiZmZjZTcxOTIvdGV4dHJlZ2lvbjoyZDQ3ZmYwMGNhZTk0ODJmOGYwODYwZGJmZmNlNzE5Ml8xNTcx_e100ebc5-c845-4c86-88ca-2b72ddaaec42">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197082367624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 22, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 22,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROCRINE BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-22705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0525145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12780 El Camino Real,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">617-7600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000914475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( #! =E,T6983[0   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( #! =E.97)PC$ 8  )PG   3
M      "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ,$!V
M4U= *64N!   ,!   !@              ("!# @  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( #! =E.?H!OPL0(  .(,   -
M      "  7 ,  !X;"]S='EL97,N>&UL4$L! A0#%     @ ,$!V4Y>*NQS
M    $P(   L              ( !3 \  %]R96QS+RYR96QS4$L! A0#%
M  @ ,$!V4ZK$(A8S 0  (@(   \              ( !-1   'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( #! =E,D'INBK0   /@!   :
M  "  941  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M #! =E-ED'F2&0$  ,\#   3              "  7H2  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     )  D /@(  ,03      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nbix-20211122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="nbix-20211122.htm">nbix-20211122.htm</File>
    <File>nbix-20211122.xsd</File>
    <File>nbix-20211122_lab.xml</File>
    <File>nbix-20211122_pre.xml</File>
    <File>nbix-20211122exhibit991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nbix-20211122.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "nbix-20211122.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nbix-20211122_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbix-20211122_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nbix-20211122.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "nbix",
   "nsuri": "http://www.neurocrine.com/20211122",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20211122.htm",
      "contextRef": "ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.neurocrine.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20211122.htm",
      "contextRef": "ic8b9e25f45f74df9beb7c8b27a101baf_D20211122-20211122",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000914475-21-000062-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000914475-21-000062-xbrl.zip
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MJF6]'[* O&<]&A4?!4N_(KQ[(G'9GIOX4_A?/Q]$^_\/4$L#!!0    ( #!
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ML-ZD=<*^?-UZ!</]VG\_VT$GV"_V8O0'4$L#!!0    ( #! =E,MB.JC40H
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M;^7]-;R9+-*KZSFL7[LL0+>[G1=%PVN%,JE0DK!"^?>NP:8#X#\3WG(;ZS.
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M&3\S1R<OUJ^DRT=IG[SX/U!+ P04    "  P0'93KUP;%*8&  #@,   %0
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ML[/]JLN/_.+P%19Y\4I<7YVZU?;V#_9I-8_$C >X4&)+,X8@VPJ+J@FP,^F
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MXU)IL42-3#\!7^ <F4I7Z?%874O:<*LF/B(M09$/Q&.4@R5U6S%_$QNT'!S
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MYFVY7V'EWX-]\T]02P$"% ,4    "  P0'93H2[A]3\<   EH0  $0
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M  !N8FEX+3(P,C$Q,3(R97AH:6)I=#DY,2YH=&U02P4&      4 !0!- 0
&DTH

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
